



## Notice of New Tennessee Rule: Chapter 1145-01 Commissioner's Controlled Substance Monitoring Database



By Julie Loomis, RN, JD

The Tennessee Controlled Substance Monitoring Database (CSMD) rules have been amended effective January 26, 2022. The amendment requires that all healthcare practitioners, unless otherwise exempted, check the CSMD prior to issuing a Schedule II amphetamine, at the beginning of a new episode of treatment[1]; prior to the issuance of each new prescription for the first ninety (90) days of a new episode of treatment; and at least every 6 months during that course of treatment.





This rule change means that Schedule II amphetamines constitute a third class of drugs triggering a check (opioids and benzodiazepines being the two current classes) and is the result of the CSMD Committee's determination that Schedule II amphetamines demonstrate a high potential for abuse. As with opioids and benzodiazepines, an authorized healthcare practitioner's delegate may check the controlled substance database on behalf of the healthcare practitioner who is prescribing Schedule II amphetamines.

The rule amendment also increases the list of mandatory fields for pharmacy and prescriber dispenser reporting information to the CSMD.

This table provides the links for each state's Prescription Drug Monitoring Program (PDMP/CSMD) information.

Alabama	https://www.alabamapublichealth.gov/PDMP/
Arkansas	https://www.healthy.arkansas.gov/programs-services/topics/prescription-mo
Georgia	https://dph.georgia.gov/pdmp
Indiana	https://www.in.gov/bitterpill/prescribing-resources/inspect/
Kentucky	https://chfs.ky.gov/agencies/os/oig/dai/deppb/Pages/kasper.aspx
Mississippi	https://pmp.mbp.ms.gov/laws-regulations/
Missouri	https://missouri.pmpaware.net/identities/new
North Carolina	https://www.ncdhhs.gov/divisions/mental-health-developmental-disabilities-carolina-drug-control-unit/nc-controlled-substances-reporting-system
Oklahoma	https://www.obndd.ok.gov/registration-pmp/pmp





South Carolina https://scdhec.gov/sites/default/files/media/document/PMPLaw\_0.pdf

Tennessee https://www.tn.gov/health/health-program-areas/health-professional-boards/document/PMPLaw\_0.pdf

Tennessee https://www.tn.gov/health/health-program-areas/health-professional-boards/document/PMPLaw\_0.pdf

Tennessee https://www.pharmacy.texas.gov/PMP/

Virginia https://www.dhp.virginia.gov/PractitionerResources/PrescriptionMonitoringParticles.

As always, SVMIC is here for you and happy to answer any questions you may have by email at ContactSVMIC@svmic.com or 800.342.2239. You may also contact the licensure board in your state for additional information.

[1] A "new episode of treatment" means a prescription for a controlled substance that has not been prescribed by that healthcare practitioner within the previous six (6) months.

The contents of The Sentinel are intended for educational/informational purposes only and do not constitute legal advice. Policyholders are urged to consult with their personal attorney for legal advice, as specific legal requirements may vary from state to state and/or change over time.